# Leerink 給予 Absci 新的優於大盤評級後股價上漲，指出其催化劑路徑。

*biotech · news · 2026-06-05 · FinanzNachrichten*

## Key points

- Veru 股價在宣布與 Novo Nordisk 合作後上漲。
- Health Catalyst 在剝離其營收工作流程及分析軟體業務後股價上漲。
- Leerink 給予 Absci 新的優於大盤評級，並提及其催化劑路徑後，Absci 股價攀升。
- Alvotech 已向 FDA 重新提交其生物製劑許可申請（BLA）。

05:00Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesenDoAbsci climbs after New Outperform at Leerink on catalyst path08.05.Absci outlines ABS-201 interim 13-week data in H2 2026 while adding ABS-202 and funding plans into H1 202805:00Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen

**Companies:** Novo Nordisk, Veru, Health Catalyst, Absci
**Countries:** Iceland

[Read the full story on FinanzNachrichten](https://www.finanznachrichten.de/nachrichten-2026-06/68686977-top-biotech-gainers-veru-teams-up-with-nvo-absi-on-watch-alvo-resubmits-blas-to-fda-020.htm)

---

Canonical: https://newsio.io/zh-TW/n/78943deb-d8de-4754-bdf0-b1c39b0c26e0/leerink-absci-absci-2026-abs-201-13
Summarized by Newsio from FinanzNachrichten. https://newsio.io/how-it-works